AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05670808
Drug: Epinephrine injection
RxNorm normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different doses on epinephrine will be administered to study arms to observe its impact on blood loss
Trial: NCT04776629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for orticumab, containing all components of formulation except the active ingredient
Trial: NCT04487613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT04982575
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (semaglutide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Trial: NCT04982575
Drug: Placebo (cagrilintide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cagrilintide) administered s.c. (subcutaneously, under the skin) once weekly.~Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Trial: NCT05430243
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diuretics as clinically indicated
Trial: NCT06238011
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline total volume50 ml prepared by nurse anesthetist at preprocedure room, start Normal Saline by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass. Record patients data by nurse anesthetist
Trial: NCT05362188
Drug: Nicotinamide Topical
RxNorm normalized name: nicotinamide topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with discoid lupus erythematosus (face \& scalp) will be given topical nicotinamide in two concentrations (2\&4%) to apply twice daily for 12 consecutive weeks and then follow up.~Topical nicotinamide will be prepared in different forms (cream \& gel).
Trial: NCT05339373
Drug: Airtal® film-coated tablet 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airtal ® is manufactured by Gedeon Richter- RUS, Russia / Gedeon Richter, Hungary. Each tablet contains 100 mg of aceclofenac.
Trial: NCT06229067
Drug: Cyclophosphamide (tablet)
RxNorm normalized name: cyclophosphamide Oral Tablet
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic oral cyclophosphamide 50 mg daily. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT06229067
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic oral capecitabine 500 mg three times daily. Capecitabine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Trial: NCT06183736
Drug: CVL237 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL237 tablets, 200 mg, taken with food once daily for 28 consecutive days as a treatment cycle.
Trial: NCT04578873
Drug: QPX7831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT04578873
Drug: placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral matched placebo capsule
Trial: NCT04872686
Drug: 0.6% PVP-I oral and nasal spray to moderately ill COVID-19 positive patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of participants 768 COVID-19 positive, moderately ill admitted patient who will receive intervention~Step 1: Enrollment of the study populations by applying inclusion and exclusion criteria Step 2: Randomization to allocate experimental and controlled group by using table of random number Step 3: Application of 0.6% PVP-I spray to experimental group and distilled water to control group Step 4: Follow up (waiting for 2-5 minutes) Step 5: Collection of nasopharyngeal and oropharyngealsawab for RT-PCR test for both group Step 6: Observation of the patients for 30 minutes for possible early adverse effects (if any) and subsequent management (if needed).~Step 7: Analysis data collection, data processing and analysis by using SPSS software.
Trial: NCT04872686
Drug: 0.6% PVP-I Oral and nasal spray to asymptomatic to mild COVID-19 patient having multiple comorbidity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of participants 20 asymptomatic to mild COVID -19 patients having multiple comorbidity who will receive intervention~Step 1: Selection of 20 patients randomly with no or mild symptoms and obtain their consent for the further tests.~Step 2: Collection of 2nd, 3rd and 4th sample from nasopharynx and oropharynx hourly Step 3: Data collection, data processing and analysis by using SPSS software
Trial: NCT04872686
Drug: 0.6% PVP-I Oral and nasal spray to healthy volunteer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of participants 10 healthy individual who accept intervention 0.6% PVP-I oronasal spray~Step 1: Selection of 10 healthy volunteers randomly who will be selected for using 0.6% PVP-I Oro-Nasal spray 2 puff inside both nostrils and mouth 3 to 4 times a day for one month.~Step 2: Collection of blood \& urine of participants on day 0, 10, 20, 30 for determination of any change in biochemical marker (thyroid, kidney and liver functions will be done) Step 3: Data collection, data processing and analysis by using SPSS software
Trial: NCT05256108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered a single dose of 6 capsules containing placebo in a randomized crossover manner
Trial: NCT05523102
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac/NSAID
Trial: NCT05402189
Drug: Ketodex, Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group.~Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively .~Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.
Trial: NCT05325177
Drug: High Dose Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (20-10-10 mg/kg) 1 dose every 24 hours after enrollment, for a total of 3 doses
Trial: NCT05147415
Drug: Tesomet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination
Trial: NCT05264038
Drug: OC514 (Mid dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid dose level of OC514
Trial: NCT06549842
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention for this study is the dose of heparin. Patients randomized to group 1 will receive a heparin dose of 50U/kg and those in group 2 will receive a lower dose of heparin at 25U/kg. Recovery period for group 1 would be 2 hours whereas for group 2 would be 1 hour.
Trial: NCT05244057
Drug: Placebo of Hepalatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c., qd for 48 weeks
Trial: NCT04280692
Drug: Artemether lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three day curative regimen 20mg/120mg
Trial: NCT06465862
Drug: Biktarvy Pill
RxNorm normalized name: Biktarvy Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biktarvy prescribed with TruTag system and tagged with TruTag microparticles.
Trial: NCT06058546
Drug: Jiuweihuaban Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiuweihuaban pill placebo 1 bag(12 g placebo per bag),p.o.,tid,for 12weeks.
Trial: NCT05029037
Drug: High doses of intravenous vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) High doses of intravenous vitamin C for seven (7) days.
Trial: NCT06525350
Drug: HB1801 (docetaxel, albumin-bound）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An improved new formulations of docetaxel
Trial: NCT04447898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Trial: NCT04565145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given three placebo capsules per day for one week
Trial: NCT01451450
Drug: QGE031
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QGE031 liquid for subcutaneous injection.
Trial: NCT01451450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo liquid for subcutaneous injection.
Trial: NCT05587322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally via tablet
Trial: NCT06008652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05005507
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF film-coated tablet will be administered orally once daily.
Trial: NCT05511870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Trial: NCT04899180
Drug: 99mTc-PYP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioisotope used by SPECT/CT imaging
Trial: NCT05079672
Drug: 0,9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.
Trial: NCT05395117
Drug: AZD5462
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Arm A: Participants will receive the IMP, AZD5462 Dose A starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin~Treatment Arm B: Participants will receive the IMP, AZD5462 Dose B starting on Day 6 and continued until Day 18 and the following approved medicinal products:~* Midazolam~* Rosuvastatin~* Digoxin
Trial: NCT05395117
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive rosuvastatin as a single dose administered with digoxin at the same time in the morning of Day 2, Day 6, and in the morning of Day 16 in both the arms.
Trial: NCT05164770
Drug: R-CHOP; R-DA-EPOCH; R-HD MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP: Rituximab 375mg/m2 d0, Cyclophosphamide 750mg/m2 d1, Doxorubicin 50mg/m2 or Doxorubicin liposome 30-40 mg /m2 d1, Vincristine 1.4mg/m2 or Vindesine 3mg/m2 d1, Prednisone 100mg d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-DA-EPOCH: Rituximab 375mg/m2 d0, Etoposide 50mg/m2, Epirubicin 15mg/m2, Vincristine 0.4mg/ m2, d1-4, Cyclophosphamide (CTX) 750mg/ m2 d5, Prednisone 60mg/ m2 d1-5. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.~R-HD MTX: Rituximab 375mg/m2 d0, Methotrexate 3.5g/m2 d1. Every 21 days is one cycle, which can be extended to 28 days per cycle according to patients' specific tolerance to chemotherapy.
Trial: NCT04528667
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT05098522
Drug: IRL201104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lyophilised powder for reconstitution for IV dosing
Trial: NCT05098522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for IRL201104
Trial: NCT06323681
Drug: Peginterferon α-2b based treatment group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.
Trial: NCT06323681
Drug: NAs monotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.
Trial: NCT05061693
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT05061693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT04605978
Drug: S95011 concentrate for solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
Trial: NCT05339633
Drug: [14C]-D-0502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: \[14C\]-D-0502 and D-0502
Trial: NCT05791097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusions will consist of a sterile, normal saline solution. Placebo will be administered on Day 1 of each 21-day cycle
Trial: NCT04717752
Drug: Troprilin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triptorelin acetate injection
Trial: NCT04605978
Drug: Placebo concentrate for solution for infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration every 2 weeks until week 4 and then every 3 weeks until week 10.
Trial: NCT02511418
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04927780
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT04927780
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV
Trial: NCT05344443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo that looks and tastes like Lemborexant tablets
Trial: NCT04771572
Drug: LP-118
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
Trial: NCT06576180
Drug: Anti-PD-1 Drugs
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 Drugs 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Trial: NCT05532111
Drug: Glucocorticoid combined with cyclophosphamide induction + maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PC-C group: The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d), and the dose was gradually reduced after 4-8 weeks, and then stopped within 6-9 months. Cyclophosphamide 750mg/m2 (adjusted according to eGFR and other conditions), once a month, intravenous pulse therapy. CTX maintenance therapy.
Trial: NCT05348772
Drug: AmnioPul-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem / stromal cells, MSC
Trial: NCT00261586
Drug: aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04730596
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline in a labeled syringe
Trial: NCT05644054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered a one-time dosage of 0.2 mg/kg of a placebo consisting of an inactive oil.
Trial: NCT04911777
Drug: Pentarlandir™ UPPTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Trial: NCT04911777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Trial: NCT05153070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Placebo with an identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 consecutive days) then then every week between Day 63 and Day 354.
Trial: NCT06209580
Drug: AMT-253 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT00046137
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00239265
Drug: Tamuslosin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05024188
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.
Trial: NCT05006287
Drug: Non-vitamin K oral anticoagulants (NOACs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC Group (Intervention):~Patients randomized to the NOAC group will receive a NOAC dosed according to the Canadian monograph for the respective indication. Patients receiving a NOAC before cardiac surgery will resume the same NOAC as pre-operatively, whereas patients not previously receiving a NOAC will preferentially receive apixaban according to local practice. The NOAC will be started no earlier than post-operative day 5 and based on the standard protocol depending on whether the patient has a pre-existing indication for anticoagulation or new indication (e.g. post-operative atrial fibrillation).~Patients at high risk of thrombosis and low risk of bleeding will receive a standardized bridging protocol as early as post-operative day 3 with unfractionated heparin infusion or low molecular weight heparin until the NOAC is initiated.
Trial: NCT06699420
Drug: Qishenyiqi dripping pills 1 bag, three times a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months
Trial: NCT06699420
Drug: Placebo 1 bag, three times a day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 1 bag once, three times a day, 12 months
Trial: NCT04610801
Drug: Nasal Spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to placebo and Xlear
Trial: NCT00133419
Drug: Vitamin + Zinc + micronutrient mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00133419
Drug: Vitamin A + Zinc
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06575478
Drug: Dihuang Baoyuan Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihuang Baoyuan Granules
Trial: NCT05584956
Drug: L_carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-carnitine stabilizes red blood cell membranes and thus improves the anemic state\[
Trial: NCT05533593
Drug: Aminoglycoside
RxNorm normalized name: Aminoglycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatients using aminoglycoside
Trial: NCT05936060
Drug: PLACEBO COMPARATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of plasmalyte as a vehicle for MSC
Trial: NCT04582539
Drug: INCB000928
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB000928 will be administered once daily.
Trial: NCT05188261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of placebo administered rectally (as a low-volume \[20 mL\] enema) following a fast of at least 6 hours.
Trial: NCT05653479
Drug: UPB-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPB-101 Subcutaneous injection
Trial: NCT00357981
Drug: ORTHO EVRA, the contraceptive patch
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05018182
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2800 mg/m² civ(46 h) Q2w before surgery rection
Trial: NCT05018182
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m² d1-14 po Q3w after surgery rection
Trial: NCT03051451
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
Trial: NCT06431932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a corresponding number of placebo capsules for two consecutive days.
Trial: NCT05440045
Drug: 6MW3211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MW3211 injection, 30mg/kg, Q2W
Trial: NCT06344195
Drug: Naproxen Sodium 550mg
RxNorm normalized name: Naproxen Sodium 550mg Oral tablet
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 550mg (as needed, SOS) for 6 days
Trial: NCT05382819
Drug: FRTX-02 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DYRK-1A Inhibitor